KRAS and non-small cell lung carcinoma: A previous clinicopathological study also showed LADC with KRAS mutation were more likely to invade visceral pleura than LADC without the mutation suggesting negative prognostic impact of KRAS mutation,30 though the frequency of visceral pleural invasion was not different between NSCLC with KRAS mutant (30%, 3/10) and KRAS‐WT (17/65; p = 0.45, Fisher's exact test) in the TMDU cohort.